| 前收盘价格 | 143.57 |
| 收盘价格 | 141.02 |
| 成交量 | 2,486,741 |
| 平均成交量 (3个月) | 2,979,421 |
| 市值 | 30,205,288,448 |
| 价格/销量 (P/S) | 63.59 |
| 股市价格/股市净资产 (P/B) | 33.68 |
| 52周波幅 | |
| 利润日期 | 7 May 2026 |
| 营业毛利率 | -265.93% |
| 营业利益率 (TTM) | -247.61% |
| 稀释每股收益 (EPS TTM) | -5.93 |
| 季度收入增长率 (YOY) | 22.90% |
| 总债务/股东权益 (D/E MRQ) | 1,316.96% |
| 流动比率 (MRQ) | 5.86 |
| 营业现金流 (OCF TTM) | -761.93 M |
| 杠杆自由现金流 (LFCF TTM) | -480.63 M |
| 资产报酬率 (ROA TTM) | -36.25% |
| 股东权益报酬率 (ROE TTM) | -890.75% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Insmed Incorporated | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.0 |
| 内部交易活动 | 0.0 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -3.5 |
| 平均 | -0.10 |
|
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Growth |
| 内部持股比例 | 0.75% |
| 机构持股比例 | 110.72% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 241.00 (TD Cowen, 71.98%) | 购买 |
| 中 | 218.00 (55.57%) | |
| 低 | 162.00 (Morgan Stanley, 15.61%) | 保留 |
| 平均值 | 214.92 (53.37%) | |
| 总计 | 11 购买, 1 保留 | |
| 平均价格@调整类型 | 165.27 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Mizuho | 24 Feb 2026 | 204.00 (45.58%) | 购买 | 158.62 |
| HC Wainwright & Co. | 23 Feb 2026 | 230.00 (64.13%) | 购买 | 159.03 |
| 18 Dec 2025 | 230.00 (64.13%) | 购买 | 166.55 | |
| Wells Fargo | 20 Feb 2026 | 208.00 (48.43%) | 购买 | 164.91 |
| 16 Dec 2025 | 234.00 (66.99%) | 购买 | 200.67 | |
| Morgan Stanley | 30 Jan 2026 | 162.00 (15.61%) | 保留 | 156.87 |
| Barclays | 28 Jan 2026 | 231.00 (64.85%) | 购买 | 155.89 |
| Roth Capital | 23 Jan 2026 | 212.00 (51.29%) | 购买 | 156.21 |
| RBC Capital | 21 Jan 2026 | 200.00 (42.72%) | 购买 | 156.32 |
| 18 Dec 2025 | 195.00 (39.16%) | 购买 | 166.55 | |
| UBS | 06 Jan 2026 | 215.00 (53.43%) | 购买 | 175.07 |
| Goldman Sachs | 18 Dec 2025 | 225.00 (60.57%) | 购买 | 166.55 |
| 15 Dec 2025 | 258.00 (84.11%) | 购买 | 196.92 | |
| Guggenheim | 18 Dec 2025 | 221.00 (57.71%) | 购买 | 166.55 |
| TD Cowen | 18 Dec 2025 | 241.00 (71.98%) | 购买 | 166.55 |
| 11 Dec 2025 | 269.00 (91.96%) | 购买 | 195.24 | |
| Cantor Fitzgerald | 16 Dec 2025 | 230.00 (64.13%) | 购买 | 200.67 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BRENNAN DAVID R | - | 159.03 | -6,000 | -954,180 |
| SHAROKY MELVIN MD | 148.61 | 148.61 | -100 | -14,861 |
| SMITH MICHAEL ALEXANDER | - | 158.62 | -24,774 | -3,929,652 |
| 累积净数量 | -30,874 | |||
| 累积净值 ($) | -4,898,693 | |||
| 累积平均购买 ($) | 148.61 | |||
| 累积平均卖出 ($) | 155.42 | |||
| 内部人员交易波幅 ($) | ||||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| SHAROKY MELVIN MD | 董事 | 25 Feb 2026 | 处理 (-) | 1,072 | 148.61 | 159,310 |
| SHAROKY MELVIN MD | 董事 | 25 Feb 2026 | 获得 (+) | 972 | 148.61 | 144,449 |
| SMITH MICHAEL ALEXANDER | 职员 | 24 Feb 2026 | 自动卖出 (-) | 24,774 | 158.62 | 3,929,652 |
| SMITH MICHAEL ALEXANDER | 职员 | 24 Feb 2026 | 执行期权 | 20,248 | - | - |
| BRENNAN DAVID R | 董事 | 23 Feb 2026 | 处理 (-) | 6,000 | 159.03 | 954,180 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合